Efficient immune recognition of tumor cells is the foundation of anti‐tumor immunity; thus, tumor self‐antigen presentation or cross‐presentation by immune cells such as macrophages are vital for immunity‐based therapies.[55] However, the antigen‐presentation ability of TAMs is often impaired, which results in reduced T‐cell activation and proliferation.[56] Drawing from these findings, we further assessed how MHC‐I presentation by MARCO+ TAMs contributes to T cell dysfunction. This evidence concerns the gene MARCO and neoplasm.